Dr. Kutlar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1120 15th St
Augusta, GA 30912Phone+1 706-721-2505Fax+1 706-721-1500
Education & Training
Medical College of GeorgiaFellowship, Hematology and Medical Oncology, 1991 - 1992- Medical College of GeorgiaResidency, Internal Medicine, 1990 - 1991
Ankara University FOMClass of 1971
Certifications & Licensure
GA State Medical License 1991 - 2025
Clinical Trials
- Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease Start of enrollment: 2010 Nov 01
Publications & Presentations
PubMed
- Enhanced vasoconstriction in sickle cell disease is dependent on ETA receptor activation.John Miller Allan, Brandon M Fox, Malgorzata Kasztan, Gillian C Kelly, Patrick A Molina
Clinical Science. 2024-12-04 - 1 citationsSurvival of transfused red blood cells from a donor with alpha-thalassemia trait in a recipient with sickle cell disease.Marianne E M Yee, Mischa L Covington, Patricia E Zerra, James W McCoy, Kirk A Easley
Transfusion. 2024-06-01 - 1 citationsExpert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA modified Delphi...Julie Kanter, Kenneth I Ataga, Neha Bhasin, Stephanie Guarino, Abdullah Kutlar
Annals of Hematology. 2024-06-01
Abstracts/Posters
- Crizanlizumab 5.0 Mg/Kg Exhibits a Favorable Safety Profile in Patients with Sickle Cell Disease: Pooled Data from Two Phase II StudiesAbdullah Kutlar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Crizanlizumab Treatment Is Associated with Clinically Significant Reductions in Hospitalization in Patients with Sickle Cell Disease: Results from the Sustain StudyAbdullah Kutlar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Downregulation of Cytoskeletal Protein Kazrin in Lung Endothelial Cells of Preclinical Sickle Cell Disease Mouse Model - Essential Role of Endothelial Barrier FunctionAbdullah Kutlar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Established Prevention of Vaso-Occlusive Crises with Crizanlizumab Is Further Improved in Patients Who Follow the Standard Treatment Regimen: Post-Hoc Analysis of the ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Other
- Laboratory diagnosis of the hemoglobinopathiesKutlar A, Kutlar F
http://www.uptodate.com/contents/laboratory-diagnosis-of-the-hemoglobinopathies
UpToDate, Wolters Kluwer Health - 2012-03-13
Press Mentions
New Drug Boosts Foetal Haemoglobin to Fight Sickle Cell DiseaseMay 18th, 2023
Research Program Aimed at Diversity Brings Young Scientists to MCG Through July 30, 2019July 17th, 2019
Novartis’ Crizanlizumab Relieves Patients from Sickle Cell Pain CrisisOctober 10th, 2018- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
